ME/CFS: Understanding Chronic Fatigue Syndrome

836,000 to 2.5 Million Americans — and Still No Approved Drug

Between 836,000 and 2.5 million Americans have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), yet the illness has no FDA-approved treatment and remained without a standardized diagnostic framework until 2015. An Institute of Medicine (IOM) report published that year — commissioned specifically because the field was in conceptual disarray — proposed a new name and a new evidence-based diagnostic criteria set. The report concluded that ME/CFS is "a serious, chronic, complex, systemic disease that frequently and dramatically limits the activities of the patients who have it." It is not a psychiatric condition masquerading as physical illness.

The 2015 IOM Renaming

The IOM's 2015 report proposed renaming the illness Systemic Exertion Intolerance Disease (SEID) to capture its cardinal feature. The name did not achieve universal adoption — clinicians largely continue using ME/CFS — but the SEID diagnostic criteria it introduced became widely referenced. The report synthesized more than 9,000 published articles and represented the most comprehensive evidence review of ME/CFS ever undertaken.

Post-Exertional Malaise: The Defining Symptom

Post-exertional malaise (PEM) is the hallmark of ME/CFS and the feature that most distinguishes it from other fatigue conditions like depression or anemia. PEM is not ordinary tiredness after exercise. It is a delayed, often severe worsening of symptoms — cognitive, immunological, and physical — triggered by physical or mental exertion that would be well-tolerated by a healthy person. Crucially, it is delayed: onset typically occurs 12–48 hours after the triggering activity and can last days to weeks.

• PEM can be triggered by physical activity, cognitive effort ("brain fog"), emotional stress, sensory overload, or even minor infections
• Objective evidence: a 2-day cardiopulmonary exercise test (CPET) demonstrates significantly reduced oxygen uptake (VO₂ max) on the second test in ME/CFS patients but not in controls — a unique finding not seen in deconditioning or depression
• The biological mechanism may involve mitochondrial dysfunction, impaired cellular energy metabolism, and dysregulated immune activation
• PEM distinguishes ME/CFS from idiopathic chronic fatigue, which does not require this symptom

SEID Diagnostic Criteria

The SEID criteria require all three of the following, plus at least one of the two additional criteria:

Required (all three): (1) A substantial reduction or impairment in the ability to engage in pre-illness activities that persists for more than 6 months; (2) post-exertional malaise; (3) unrefreshing sleep.

At least one of: (4) cognitive impairment; (5) orthostatic intolerance.

The Graded Exercise Therapy Controversy

For years, graded exercise therapy (GET) and cognitive behavioral therapy (CBT) were the only treatments recommended by bodies like NICE in the UK, based largely on the PACE trial (2011). The premise of GET was that ME/CFS is perpetuated by deconditioning and fear-avoidance; gradual activity increases would restore function.

This model has been extensively challenged. The PACE trial itself became controversial after reanalysis of its data: when using the original outcome thresholds, recovery rates were far lower than initially reported. Patient advocacy groups and independent researchers noted that GET caused significant harm in a large proportion of patients with ME/CFS — specifically through triggering PEM cycles.

In 2021, NICE reversed its guidance: GET is no longer recommended for ME/CFS, and CBT is no longer listed as a treatment for the underlying illness (though it may help with coping and comorbid conditions). Energy management — specifically "pacing" — is now the endorsed behavioral approach.

Long COVID and ME/CFS: A Critical Overlap

SARS-CoV-2 infection produces ME/CFS-like illness in a substantial subset of patients. A 2021 study in Nature Medicine found that 57% of Long COVID patients met criteria for ME/CFS at 6 months post-infection. PEM is reported by approximately 89% of Long COVID patients meeting ME/CFS criteria. This overlap has dramatically increased funding and research attention for ME/CFS — a condition that had previously received disproportionately little NIH funding relative to its disease burden.

• NIH committed $1.15 billion over 4 years (2021) to study Long COVID, much of it relevant to ME/CFS mechanisms
• Shared pathological features: mitochondrial dysfunction, microglial activation, small fiber neuropathy, and mast cell activation
• Reactivation of latent herpesviruses (EBV, HHV-6) documented in both Long COVID and classic ME/CFS
• The overlap has accelerated biomarker research that may finally yield objective diagnostic tests

Current Research Directions

No drug is FDA-approved for ME/CFS, but several trials are ongoing. Low-dose naltrexone (LDN, 1.5–4.5 mg) has anecdotal support and anti-neuroinflammatory mechanisms under investigation. BC007, targeting autoantibodies against G-protein coupled receptors, is in clinical trials in Germany. IVIG has been studied in subgroups. The fundamental unmet need is a reliable biomarker to stratify patients — because "ME/CFS" likely encompasses several distinct biological subgroups.

This article is for informational purposes only. Consult a qualified healthcare professional.